Cargando...
Hitting KRAS When It’s Down
KRAS, one of the most prevalent oncogenes and sought-after anticancer targets, has eluded chemists for decades until an irreversible covalent strategy targeting a specific mutation (G12C) paved the way for the first KRAS inhibitors to reach the clinic. MRTX849 is one such clinical candidate with pro...
Gardado en:
| Publicado en: | J Med Chem |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Chemical
Society
2020
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7467708/ https://ncbi.nlm.nih.gov/pubmed/32568546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00785 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|